Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.95 USD | +4.77% | +16.18% | -55.06% |
04-26 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
04-12 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
Business Summary
Number of employees: 597
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Product
94.8
%
| 126 | 94.7 % | 222 | 94.8 % | +76.62% |
Service
5.2
%
| 7 | 5.3 % | 12 | 5.2 % | +75.24% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 133 | 100.0 % | 234 | 100.0 % | +76.55% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Mark Foley
CEO | Chief Executive Officer | 58 | 04/09/17 |
Tobin Schilke
DFI | Director of Finance/CFO | 49 | 04/11/18 |
Azita Nejad
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/13 |
Conor Gallagher
CTO | Chief Tech/Sci/R&D Officer | - | 08/05/18 |
David Hollander
CTO | Chief Tech/Sci/R&D Officer | 50 | 16/10/22 |
Jessica Serra
IRC | Investor Relations Contact | - | - |
Erica Jordan
PRN | Corporate Officer/Principal | - | - |
Dwight Moxie
LAW | General Counsel | 48 | 31/01/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Angus Russell
CHM | Chairman | 68 | 28/02/11 |
Mark Foley
CEO | Chief Executive Officer | 58 | 04/09/17 |
Jill Beraud
BRD | Director/Board Member | 63 | 03/06/19 |
Julian Gangolli
BRD | Director/Board Member | 66 | 30/06/16 |
Carey Kolaja
BRD | Director/Board Member | 51 | 28/02/21 |
Olivia Ware
BRD | Director/Board Member | 67 | 05/03/21 |
Vladimir Coric
BRD | Director/Board Member | 53 | 28/02/23 |
Christian Nolet
BRD | Director/Board Member | 67 | 15/07/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 104,215,614 | 95,385,648 ( 91.53 %) | 0 | 91.53 % |
Company contact information
Revance Therapeutics, Inc.
1222 Demonbreun Street Suite 2000
37203, Nashville
+615 724 7755
http://www.revance.comSector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.06% | 393M | |
-3.79% | 87.06B | |
+1.45% | 40.25B | |
-15.94% | 31.09B | |
+52.66% | 24.74B | |
-14.50% | 15.91B | |
-9.12% | 11.96B | |
-14.38% | 11.92B | |
-42.56% | 11.61B | |
+4.87% | 8.73B |
- Stock Market
- Equities
- RVNC Stock
- Company Revance Therapeutics, Inc.